Brief: Orexo Resubmits NDA For Izipry To FDA
29/09/2026 14:46
BRIEF-Orexo Resubmits NDA For Izipry To FDA Sept 29 (Reuters) - Orexo AB ORX.ST:
OREXO AB: OREXO RESUBMITS NDA FOR IZIPRY™ TO THE FDA, A HIGH-DOSE RESCUE MEDICATION FOR OPIOID OVERDOSE
RESUBMITS NDA FOR IZIPRY TO FDA ON SEPT 29, 2026
EXPECTS FDA REVIEW TO COMMENCE AFTER ACCEPTANCE OF RESUBMISSION
Source text: ID:nMFNQBpPr
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))